Core Insights - Oxford BioTherapeutics (OBT) has announced a multi-year collaboration with Roche to discover novel antibody-based therapeutics for cancer treatment [1][3] - The collaboration will utilize OBT's OGAP®-Verify discovery platform to identify and validate cancer targets, with Roche leading further research and commercialization efforts [3][4] - OBT is set to receive up to US1 billion, along with royalties on net sales [3][9] Company Overview - OBT is a clinical stage oncology company focused on developing first-in-class antibody-based therapies, including Bispecific Antibodies and Antibody Drug Conjugate (ADC) therapeutics [5] - The company aims to discover and validate next-generation ADC targets, enhancing the capabilities of biopharma in identifying human targets [6] - OBT's lead clinical program, OBT076, targets advanced or refractory solid tumors, with a focus on cancers where CD205 is overexpressed [7] Collaboration Details - The partnership combines OBT's innovative target discovery platform with Roche's expertise in drug development, aiming to accelerate the development of new cancer therapies [4][9] - The collaboration emphasizes a patient-centric approach and aims to address significant unmet needs in oncology [4] - OBT's previous partnerships with major companies like Boehringer Ingelheim and ImmunoGen validate its pipeline and development capabilities [8]
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer